Efficacy of cAC10-vcMMAE in HD and ALCL models. Antitumor activity of cAC10-vcMMAE on subcutaneous Karpas 299 and L540cy HD tumor models in SCID mice. Mice were implanted with 5 × 10⁶ Karpas 299 ALCL cells (A) or 2 × 10⁷ L540cy Hodgkin disease cells (B) into the right flank. Groups of mice (5/group) were left untreated (x) or received cAC10-vcMMAE at 0.3 mg/kg (○) or 1 mg/mg (•), an irrelevant IgG-vcMMAE at 1 mg/kg (⋄), or free MMAE at 0.36 mg/kg (□) (10 × the dose equivalent of 1 mg/kg ADC) on a schedule of q4d × 4 starting when the tumor size in each group of 5 animals averaged approximately 100 mm³.